Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
Sight Sciences (Nasdaq: SGHT) announced participation in the Piper Sandler Annual Virtual Healthcare Conference on November 22, 2021. The company focuses on innovative eyecare technology aimed at transforming care standards. Notable products include the OMNI® Surgical System, a minimally invasive glaucoma surgery device, and the TearCare® System, designed for treating evaporative dry eye disease. A recording of the fireside chat will be accessible on their investor website after the event.
- None.
- None.
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.
A recording of the fireside chat will be available beginning on Monday, November 22, 2021, at 10:00am ET. Interested parties may access the webcast on the “Investors” section of the company’s website at: https://investors.sightsciences.com/
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. The Company has a 510(k) pending for the clearance of the TearCare System for an expanded indication for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2021 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
When is Sight Sciences participating in the Piper Sandler Annual Virtual Healthcare Conference?
What products does Sight Sciences offer?
Where can I access the webcast for Sight Sciences' conference participation?
What is the significance of the OMNI® Surgical System?
What indication is pending for the TearCare® System?
